Sona Nanotech Inc
CNSX:SONA
Net Margin
Sona Nanotech Inc
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| CA |
S
|
Sona Nanotech Inc
CNSX:SONA
|
40.2m CAD | N/A | |
| US |
P
|
PerkinElmer Inc
LSE:0KHE
|
974.7B USD |
10%
|
|
| US |
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
152.3B USD |
15%
|
|
| US |
|
Danaher Corp
NYSE:DHR
|
135.4B USD |
16%
|
|
| KR |
|
Samsung Biologics Co Ltd
KRX:207940
|
71.2T KRW |
26%
|
|
| CH |
|
Lonza Group AG
SIX:LONN
|
39.6B CHF |
10%
|
|
| US |
|
Agilent Technologies Inc
NYSE:A
|
31.7B USD |
19%
|
|
| CN |
|
WuXi AppTec Co Ltd
SSE:603259
|
179.6B CNY |
27%
|
|
| US |
|
IQVIA Holdings Inc
NYSE:IQV
|
24.5B USD |
9%
|
|
| US |
|
Mettler-Toledo International Inc
NYSE:MTD
|
24.2B USD |
22%
|
|
| FR |
|
Sartorius Stedim Biotech SA
PAR:DIM
|
18.9B EUR |
7%
|
Sona Nanotech Inc
Glance View
Sona Nanotech, Inc. is a nanotechnology life sciences company, which engages in the development and manufacture of rod-shaped gold nanoparticles. The company is headquartered in Halifax, Nova Scotia and currently employs 8 full-time employees. The company went IPO on 2018-10-04. The firm is engaged in the research and development of its technology for use in multiplex diagnostic testing platforms and biomedical applications. Its core technology is a rod-shaped nanoparticle manufactured at scale with surfactants that allow the production of two different product lines (Gemini and Omni) for use in both in-vitro and in-vivo applications, such as lateral flow diagnostics and cell imaging respectively. The firm's gold nanorod particles are manufactured without the use of CTAB (cetyltrimethylammonium), eliminating the toxicity risks associated with the use of other gold nanorod technologies in medical applications. The firm also offers development services to help lateral flow producers create new lateral flow tests and improve existing tests for their product iteration.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on Sona Nanotech Inc's most recent financial statements, the company has Net Margin of 0%.
You don't have any saved screeners yet